Trial Profile
A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to less than 18 Years with Chronic Hepatitis C Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Elbasvir; Grazoprevir
- Indications Hepatitis C
- Focus Pharmacokinetics
- Acronyms MK-5172-079
- Sponsors Merck Sharp & Dohme Corp.
- 04 Aug 2020 This trial has been completed in Germany , according to European Clinical Trials Database
- 29 Jul 2020 Status changed from active, no longer recruiting to completed.
- 24 Jun 2020 Planned End Date changed from 12 Jun 2020 to 20 Jul 2020.